Unlocking the Potential of T-Cell Reprogramming: A Look at Lyell Immunopharma’s Latest Innovations and Pipeline at the 2022 SITC Annual Meeting
Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technology Exciting Developments in T-Cell Therapy Lyell Immunopharma, a pioneering company in the field of T-cell reprogramming, is set to unveil groundbreaking preclinical data at an upcoming conference. The data pertains to the incorporation of new T-cell reprogramming technology in LYL119, Lyell’s latest product candidate….